Millennium Pharmaceuticals, Inc.
FDA grants full approval for VELCADE (bortezomib) for injection
Published in Lab Business Week, May 8th, 2005
This approval expands the label to include the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. VELCADE is the only drug therapy that has demonstrated a significant survival advantage as compared to a standard therapy in relapsed MM, according to the company. Initial accelerated approval for relapsed and refractory MM was granted in May 2003. VELCADE is now fully approved in relapsed MM.
The approval was based on data from the randomized phase...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2005-05-08)
More Articles from Lab Business Week
- AEterna Zentaris, Inc.
Atrium Biotechnologies files final prospectus for $75M IPO - Access Pharmaceuticals, Inc.
Pharmaceutical company reports loss of $0.18 per share - Aeterna Zentaris Inc.
Atrium Biotechnologies finishes initial public, secondary offering of $75M - Alexion Pharmaceuticals, Inc.
Pharmaceutical firm files resale registration statement for notes - Alltracel Pharmaceuticals Plc.
Pharmaceutical company reports 355% increase in revenue - Almirall
Pharmaceutical company reaches sales of EUR900 million in 2004 - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
